文献标引:朱步东，任军.表皮生长因子受体2与乳腺癌治疗效果的预测[J/CD].中华临床医师杂志：电子版,2010,4(3):266-272.

参考文献:
[1]　Paik S，Bryant J，Tan-Chiu E，et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst，2002，94（11）：852－854.[PubMed]
[2]　Wolff AC，Hammond ME，Schwartz JN，et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol，2007，25（1）：118－145.[PubMed]
[3]　Owens MA，Horten BC，Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer，2004，5（1）：63－69.[PubMed]
[4]　Guarneri V，Giovannelli S，Ficarra G，et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases：impact on patient management. Oncologist，2008，13（8）：838－844.[PubMed]
[5]　Lipton A，Leitzel K，Ali SM，et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer，2005，104（2）：257－263.[PubMed]
[6]　Brufsky A，Lembersky B，Schiffman K，et al. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer，2005，6（3）：247－252.[PubMed]
[7]　Perez EA，Suman VJ，Davidson NE，et al. HER2 testing by local，central，and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol，2006，24（19）：3032－3038.[PubMed]
[8]　Cobleigh MA，Vogel CL，Tripathy D，et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol，1999，17（9）：2639－2648.[PubMed]
[9]　Seidman AD，Berry D，Cirrincione C，et al. CALGB 9840：Phase III study of weekly（W）paclitaxel（P）via 1-hour（h）infusion versus standard（S）3h infusion every third week in the treatment of metastatic breast cancer（MBC），with trastuzumab（T）for HER2 positive MBC and randomized for T in HER2 normal MBC. Journal of Clinical Oncology，2004，22（14 Suppl）：512.
[10]　Ali SM，Carney WP，Esteva FJ，et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer，2008，113（6）：1294－1301.[PubMed]
[11]　Lennon S，Barton C，Banken L，et al. Utility of serum HER2 extracellular domain assessment in clinical decision making：pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol，2009，27（10）：1685－1693.[PubMed]
[12]　Press MF，Finn RS，Cameron D，et al. HER-2 gene amplification，HER-2 and epidermal growth factor receptor mRNA and protein expression，and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res，2008，14（23）：7861－7870.[PubMed]
[13]　Cameron D，Casey M，Press M，et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab：updated efficacy and biomarker analyses. Breast Cancer Res Treat，2008，112（3）：533－543.[PubMed]
[14]　Harris L，Fritsche H，Mennel R，et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol，2007，25（33）：5287－5312.[PubMed]
[15]　Goldhirsch A，Wood WC，Gelber RD，et al. Progress and promise：highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol，2007，18（7）：1133－1144.[PubMed]
[16]　Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med，2007，357（1）：39－51.[PubMed]
[17]　Johnston S，Trudeau M，Kaufman B，et al. Phase Ⅱ study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2（HER-2）in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol，2008，26（7）：1066－1072.[PubMed]
[18]　Scaltriti M，Rojo F，Ocana A，et al. Expression of p95HER2，a truncated form of the HER2 receptor，and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst，2007，99（8）：628－638.[PubMed]
[19]　Pritchard KI，Shepherd LE，O'Malley FP，et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med，2006，354（20）：2103－2111.[PubMed]
[20]　Gennari A，Sormani MP，Pronzato P，et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer：a pooled analysis of randomized trials. J Natl Cancer Inst，2008，100（1）：14－20.[PubMed]
[21]　Slamon D，Eiermann W，Robert N，et al. BCIRG 006：2nd interim analysis phase Ⅲ randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel（ACT）with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab（ACTH）with docetaxel，carboplatin and trastuzumab（TCH）in Her2neu positive early breast cancer patients. 29th Annual San Antonio Breast Cancer Symposium，December 14～17，2006. San Antonio，Texas，2006：A52.
[22]　Niskanen E，Blomqvist C，Franssila K，et al. Predictive value of c-erbB-2，p53，cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer，1997，76（7）：917－922.[PubMed]
[23]　Hayes DF，Thor AD，Dressler LG，et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med，2007，357（15）：1496－1506.[PubMed]
[24]　Colomer R，Llombart-Cussac A，Lloveras B，et al. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer：a confirmatory prospective study. Cancer，2007，110（10）：2178－2185.[PubMed]